Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT00532155 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00532155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00532155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
October 31, 2011
Enrollment
913 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung